[1]叶智轶,王辉,吴靖川.维甲酸在诱导再分化治疗分化型甲状腺癌中的价值[J].国际放射医学核医学杂志,2007,31(4):221-225.
　YE Zhi-yi,WANG Hui,WU Jing-chuan.The value of retinoic acid-induced redifferentiation in the treatment of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):221-225.
点击复制

维甲酸在诱导再分化治疗分化型甲状腺癌中的价值(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
31
期数:
2007年第4期
页码:
221-225
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The value of retinoic acid-induced redifferentiation in the treatment of differentiated thyroid carcinoma
作者:
叶智轶;  王辉;  吴靖川
200092 上海, 上海交通大学医学院附属新华医院核医学科
Author(s):
YE Zhi-yi;  WANG Hui;  WU Jing-chuan
Department of Noclear Medicine, Xinhua Hospilal, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China
关键词:
分化型甲状腺癌; 维甲酸; 再分化
Keywords:
Differentiated thyroid carcinoma; Retinoic acids; Redifferentiation
分类号:
R817.5
摘要:
分化型甲状腺癌约有30%肿瘤发生去分化,以致于术后131I治疗和甲状腺素替代治疗疗效差或无效。维甲酸作为维生素A的生物活性代谢产物,对于多种细胞的发生、增殖、分化起着重要的作用。多项研究发现,维甲酸诱导再分化治疗分化型甲状腺癌的潜力巨大。
Abstract:
About 30% of differentiated thyroid carcinoma(DTC) loses its ability of differentiation, which results in poor or no effect of the radioiodine therapy and the thyroid hormone replacement therapy after operation. Retinoic acids, the biologically active metabolite of vitamin A, is of central importance for growth, proliferation and differentiation of various cells. In this review, summarized the mechanism of the dedifferentiation among the DTC, the retinoic acids-induced redifferention and the clinical use of retinoic acids. It is demonstrated by many studies that retinoic acids-induced redifferentiaon has a large potential in the treatment of DTC.

参考文献/References:

1 Grüning T,Tiepolts C,Zphel K,et al Retinoic acid for rediffer-entiation of thyroid cancer-does it hold its promise?.Eur J Endocrinol,2003,148(4):395-402.
2 Schmutzler C,Hoang-Vu C,Ruger B,et al. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses.Eur J Endocrinol,2004,150(4):547-556.
3 Elisei R,Pinchera A,Romei C,et al. Expression of thyrotropin receptor(TSH-R),thyroglobulin,thyroperoxidase,and calcitonin messenger ribonucleic acids in thyroid carcinomas:evidence of TSH-R gene transcript in medullary histotype.J Clin Endocrinol Metab,1994,78(4):867-871.
4 Kurebayashi J,Tanaka K,Otsuki T. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line,KTC-1.J Clin Endocrinol Metab,2000,85(8):2889-2896.
5 Schmutzler C,Khrle J. Innovative strategies for the treatment of thyroid cancer.Eur J Endocrinol,2000,143(1):15-24.
6 Ringel MD,Anderson J,Souza SL,et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer.Mod Pathol,2001,14(4):289-296.
7 Russo D,Manole D,Arturi F,et al. Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas.Thyroid,2001,11(1):37-39.
8 Dohan O,Baloch Z,Banrevi Z,et al. Predominant intracellular overexpression of the Na+/I- symporter(NIS) in a large sampling of thyroid cancer cases.J Clin Endocrinol Metab,2001,86(6):2697-2700.
9 Tonacchera M,Viacava P,Agretti P,et al. Benignnonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.J Clin Endocrinol Metab,2002,87(1):352-357.
10 张一帆,李彪,赵龙,等. 维甲酸诱导甲状腺癌细胞摄碘的实验研究.中华核医学杂志,2005,25(2):90-93.
11 Klopper JP,Hays WR,Sharma V,et al. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinnet-reatment.Mol Cancer Ther,2004,3(8):1011-1020.
12 Elisei R,Vivaldi A,Agate L,et al. All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor β messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes.J Clin Endocrinol Metab,2005,90(4):2403-2411.
13 Coelho SM,Vaisman M,Carvalho DP,et al. Tumor redifferentiation effect of retinoic acid:a novel therapeutic approach for advanced thyroid cancer.Curr Pharma Des,2005,11(19):2525-2531.
14 Hoang-Vu C,Bull K,Schwarz I,et al. Regulation of CD97 protein in thyroid carcinoma.J Clin Endocrinol Metab,1999,84(3):1104-1109.
15 Simon D,Korber C,Krausch M,et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer:final results of a pilot study.Eur J Nucl Med Mol Imaging,2002,29(6):775-782.
16 张一帆,贾士铨,李彪,等. 维甲酸诱导分化治疗甲状腺癌的临床研究.中华内分泌代谢杂志,2006,4(22):101-110.
17 张雯杰,郑容,林琳,等. 维甲酸诱导分化在分化型甲状腺癌治疗中的初步应用.实用癌症杂志,2005,20(4):396-401.
18 Gr nwald F,Menzel C,Bender H,et al. Redifferentiation therapyinduced radioiodine uptake in thyroid cancer.J Nucl Med,1998,39(11):1903-1906.
19 Wang W,Larson SM,Fazzari M,et al. Prognostic value of[18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.J Clin Endocrinol Metab,2000,85(3):1107-1113.
20 Simon D,K hrle J,Reiners C. Redifferentation therapy with retinoids:therapeutic option for advanced follicular and papillary thyroid carcinoma.World J Surg,1998,22(6):569-574.
21 Haugen BR,Larson LL,Pugazhenthi U. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids.J Clin Endocrinol Metab,2004,89(1):272-280.

相似文献/References:

[1]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[2]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[3]李艳玲,栾兆生.维甲酸在131I治疗分化型甲状腺癌中的应用[J].国际放射医学核医学杂志,2009,33(4):226.[doi:10.3760/cma.j.issn.1673-4114.2009.04.010]
　LI Yan-ling,LUAN Zhao-sheng.The application of retinoic acids in the 131I treatment with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(4):226.[doi:10.3760/cma.j.issn.1673-4114.2009.04.010]
[4]孟召伟,谭建.重组人促甲状腺激素和促再分化药物在分化型甲状腺癌中的应用[J].国际放射医学核医学杂志,2006,30(6):338.
　MENG Zhao-wei,TAN Jian.Application of recombinant human thyrotropin and redifferentiation drugs in differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):338.
[5]马寄晓,叶大铸.奥曲肽及其类似物用于肿瘤治疗的进展[J].国际放射医学核医学杂志,2005,29(2):79.
　MA Ji-xiao,YE Da-zhu.Advances in tumor treatment with labeled somatostatin analogues[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):79.
[6]罗全勇,朱瑞森.分化型甲状腺癌患者血清Tg和TgAb检测与结果分析应注意的问题[J].国际放射医学核医学杂志,2004,28(5):197.
　LUO Quan-yong,ZHU Rui-sen.Critical problems in the measurement and clinical evaluation of serum thyroglobulin and thyroglobulin antibody in differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):197.
[7]丁昊,叶斌,雷勇.增强DTC病灶摄取131I功能的措施[J].国际放射医学核医学杂志,2001,25(4):145.
　DING Hao,YIE Bin,LEI Yong.The augmentation of 131I uptake of DTC[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(4):145.
[8]康玉国.分化型甲状腺癌18F-FDG PET显像的临床应用[J].国际放射医学核医学杂志,2000,24(6):264.
　KANG Yuguo.Application of 18F-FDG PET scan in patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(4):264.
[9]陈可靖.甲状腺癌131I显像假阳性的分析及鉴别诊断[J].国际放射医学核医学杂志,2000,24(1):11.
　CHEN Ke-jing.The analysis and diferentiate diagnosis of false positive 131I imaging in metastatic thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(4):11.
[10]张渊琪,赵德善.分化型甲状腺癌的治疗进展[J].国际放射医学核医学杂志,2017,41(2):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]
　Zhang Yuanqi,Zhao Deshan.Advances in the treatment of differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):126.[doi:10.3760/cma.j.issn.1673-4114.2017.02.009]

备注/Memo

备注/Memo:
收稿日期:2006-12-24。
通讯作者:吴靖川(E-mail:wujingchuan@hotmail.com)
更新日期/Last Update: 1900-01-01